STANDARD PRACTICES
Supply Chain visibility alert: Unseen roadblocks ahead
by Karen Conway, Vice President, Healthcare Value, GHX
The rule reuires manufacturers to assign uniue device identifi ers (UDIs) to the label of their products and to mark those products at each packaging level with the UDIs in both human and machine- readable formats. The FDA cautioned that the UDI on labels alone would not do the trick. It is a building block necessary to unam- biguously identify products across organizations – both public and private sector – and in technology systems from electronic health records to claims databases. The FDA was also clear that the UDI rule was not a track and trace requirement; rather the UDIs would be a necessary element to make such a system possible for medical devices. While the FDA was focused on its regulatory responsibili- ties, supply chain professionals were uic to see additional benefi ts, including improved transactional effi ciency, order fulfi llment and inventory management.
W
When the UDI rule was published in 2013, it noted the potential to more effectively 1) identify adverse events and 2) target and man- age medical device recalls. That same year, the FDA published an updated version of “Strengthening Our National System for Medical Device Postmarket Surveillance,”1
which clearly depicted the vision
for UDI in electronic health records, claims data, registries and medi- cal device reports, among others. Nearly eight years later, achieving the vision of DI has been stifl ed in part due to regulatory delays and the reluctance of both providers and suppliers to do more with UDI than required by regulators. Even more disconcerting, some of those roadblocks exist within the FDA and other government agencies, as outlined in a recent perspective piece2 the American Medical Association Internal Medicine.
in the Journal of
UDI in adverse event reporting and recalls Perhaps most surprising is the lack of consistent use of UDIs for adverse events and recall management, given that both were noted in the egulatory Impact nalysis published with the fi nal rule. ess than 2 percent of the more than one million adverse event reports made in 2019 contained UDIs, while only one-tenth of medical device recalls include UDIs. The problem, in part, is that the UDI is just one of many identifi ers the FD will accept for recalls. ith adverse events, the story is even stranger. The JAMA viewpoint piece says the Freedom of Information ct offi ce at the FD often redacts the UDI if it believes it could jeopardize protected patient information. Unfortunately, that risk could be addressed by redacting only the production identifi er portion of the DI, e.g., when it contains a serial number, as opposed to the full UDI, which includes the more generic device identifi er.
UDI in claims
For years, the FDA has relied on national drug codes (NDC) in claims forms to identify and conduct post market surveillance on specifi c drugs used in patient care. The FD had envisioned the DI
UDI in COVID-19 response The supply shortages experienced during COVID-19 may be the impetus to get UDI back on track. While UDIs could not have prevented the shortages resulting from the simultaneous unprec- edented and extended global increase in demand and the constraint on global supply production and movement, the identifi ers could have made it easier to optimize availability of supplies where they are needed most. • UDI could be used by hospitals for better visibility into current inventory levels, utilization (burn) rates and anticipated needs based on patient volumes.
Hospitals could use DIs to share demand data with suppliers to help with more need driven allocation.
• The Strategic National Stockpile and other organizations managing safety stock could use UDIs, which include expiry dates, to rotate stock before it becomes unusable.
• Suppliers could let hospitals know about backorders or partial or delayed shipments using UDIs in electronic purchase order acknowledgements and advanced ship notices, allowing hospitals more time to take alternative action.
se of DIs in conjunction with classifi cation schemas and or clinically relevant attributes for products can help hospitals identify alternative vendors or supplies.
• Global adoption of UDI could help manage products being used under emergency use authorizations to help minimize counterfeit- ing and to track potential adverse events or recalls. For those of us who have been on the UDI journey, the road can seem impassable. On the other hand, if we think about why we headed in this direction in the fi rst place, the investments we
62 February 2021 • HEALTHCARE PURCHASING NEWS •
hpnonline.com
hen the U.S. Food and Drug Administration (FDA) was promoting the importance of the still unpublished UDI rule, the underlying value proposition was visibility.
would serve that purpose for medical devices; without it, claims data only says a patient received a type of device, e.g., a coronary stent, but not the specifi c brand, model or serial number of the device. In 2017, after considerable debate, the standards organization that administers claims forms agreed to add a fi eld for DIs for implant- able devices three years later, the fi eld is not yet in place, and the Centers for Medicare and Medicaid Services (CMS) would still have to mandate its consistent use.
UDI in electronic health records Both CS and the Offi ce of the National Coordinator for Health IT reuire that Hs be able to capture and store DIs for devices implanted in patients in electronic patient records and be able to share that data. Many health systems still struggle with data management, point of use capture, and interoperability that would provide for greater visibility into device performance. As mentioned earlier, UDI is a building block, but it takes a village (including hospitals, suppliers, payers, technology companies, and regulators, among others) to adopt and use the UDIs to achieve the value intended by the regulation.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70
